亚盛医药-B(06855.HK)治疗白血病创新药完成中国首例患者给药
亚盛医药-B(06855.HK)公布,公司在研原创新药MDM2-p53抑制剂APG-115的Ib期临床研究,已在中国完成首例患者给药,是APG-115在中国血液肿瘤患者中进行的首个临床研究。
该项研究为一项全国多中心Ib期临床研究,旨在评核APG-115作为单药及联合阿扎胞(甘)或阿糖胞(甘)治疗复发或难治急性髓性白血病、复发或进展高危/极高危骨髓增生异常综合症等血液肿瘤患者的安全性、药代动力学和药效动力学特徵。
集团指,APG-115是一款口服、高选择性的小分子MDM2-p53蛋白蛋白相互作用(PPI)抑制剂。APG-115是首个在中国进入临床阶段的MDM2-抑制剂,已在中国和美国展开多项治疗实体瘤的临床研究。目前,APG-115正在同步推进多个血液肿瘤适应症的全球临床开发。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.